RapidCHECK® Multi-Drug 9 Panel Test is an forensic, all inclusive, point
of use screening test for the rapid detection of 11-nor- delta 9
-Tetrahydrocannabinol -9- carboxylic acid (THC/Marijuana), Cocaine and its metabolite, benzoylecgonine, PCP (Phencyclidine), Morphine and its
related metabolites derived from opium (opiates),
Methamphetamines (including Ecstasy), Methadone, Amphetamines, Barbiturates, and Benzodiazepines in human urine at or above the system concentrations levels established as standard minimums by the National Institute
on Drug Abuse (NIDA), the World Health Organization (WHO)
and SAMHSA as shown in the chart to the right.
Note system cut-off concentrations are expressed in nanograms per milliliter.
For specific information concerning the individual drug or drug classifications
covered in this test screen see the DRUG FAQ.
SUMMARY AND EXPLANATION
Urine based screening tests for drugs of abuse range from simple immunoassay tests to complex analytical procedures. The speed and sensitivity of lateral flow based immunoassays identical to that employed in the RapidCHECK® Multi-Drug 9 Panel Screen Test have made them the most widely accepted method for screening urine for drugs of abuse. The RapidCHECK® 9 Multi-Drug Screening test is based on the principle of the highly specific immunochemical reactions of antigens and antibodies which are used for the analysis of specific compounds in human urine. The RapidCHECK® 9 Multi-Drug Screen is a rapid, visual, competitive panel immunoassay that can be used for the simultaneous, qualitative detection of the nine (9) targeted drugs and their metabolites listed above. For a description of these drugs of abuse along with other useful background information please refer to the DRUG FAQ page. The RapidCHECK® Multi-Drug Screen Panel Test is intended as an initial forensic screen for the presence of drug or drug metabolites at the time the test is performed. Because the test requires visual interpretation, it is recommended that a person other than the test subject interpret test results.
the enclosed instruction manual completely.
INTERPRETATION OF TEST RESULTS
Negative: Colored lines adjacent to each target drug name and in the control (C) regions will appear. The color intensity of the line for the target drug may be weaker or stronger than that of the control line however any line, no matter how faint should be interpreted as a negative result.
Do not attempt to correlate the intensity or color of the test lines between the
targeted drug panels. Also because development times vary for each target drug, results should not
fully interpreted until 6-8 minutes have elapsed. Some drug panels, however,
will develop test lines within 3 minutes or less producing negative results.
A very faint line on the test
region may indicate that the target drug in the sample is near the cutoff level
for the test. While these results should be considered negative, confirmation of
the sample by more analytical testing methods may be desired.
AVAILABILITY AND ORDERING
The RapidCHECK® Multi-Drug 9 Panel Test Card screens for approximately 90% of the abused illicit or prescription drugs used today in one simple to use all inclusive device. Test cassettes are individually and hermetically sealed in a foil package clearly stamped with lot number and expiration date. A comprehensive instruction sheet is included covering greater detail on test procedure, clinical accuracy and cross-reactivity charts. The RapidCHECK® Multi-Drug 9 Panel test is available in packs of 1, 3, 6, 12, 24 and 100 tests. For bulk quantities of 250 or more please contact Customer Service.
Urine Sample Validity
specimen collection containers available separately:
Urine Sample Validity
Professional specimen collection containers available separately: Specimen Containers